Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer

Launched by BARZILAI MEDICAL CENTER · Mar 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help diagnose lung cancer, specifically a type called non-small cell lung cancer (NSCLC). Researchers want to see if testing a fluid collected during a procedure called EBUS-TBNA (a method used to examine lymph nodes in the chest) can provide more information about the presence of cancer, especially when initial tests do not show any tumor cells. By analyzing the leftover fluid (known as the supernatant) using advanced genetic testing, they hope to find signs of cancer that might be missed in standard tests. This could reduce the need for more invasive procedures like surgery.

To participate, individuals must be adults suspected of having NSCLC with potential lymph node involvement and are already scheduled for the EBUS-TBNA procedure. If their initial EBUS-TBNA results show no tumor cells, they may be included in the study if they will still need surgery to remove the lymph nodes. Participants can expect the researchers to analyze both the fluid from the procedure and any tissue samples taken during surgery to compare results. This study is important because it aims to make lung cancer diagnosis more accurate and less invasive, ultimately helping to improve patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • adult (age ≥18 years) patients with high suspicion for NSCLC with thoracic lymph nodes involvement (per clinical judgement and imaging studies), planned for an EBUS-TBNA procedure
• • Subjects with negative EBUS-TBNA results (no evidence of lymph node involvement by tumor according to histology) who will require surgical resection of the thoracic lymph nodes will comprise the final study group
• Exclusion Criteria:
• • 1. Subjects unable or not willing to provide informed consent for study participation.
• • 2. Subjects in whom NSCLC will ultimately be ruled out.
• • 3. Subjects who will not require surgical resection of thoracic lymph nodes, or who will not undergo such procedure in our Medical Center for any reason